AVN 65.52 Decreased By ▼ -1.18 (-1.77%)
BAFL 29.72 Increased By ▲ 0.22 (0.75%)
BOP 4.05 Decreased By ▼ -0.03 (-0.74%)
CNERGY 3.57 Decreased By ▼ -0.05 (-1.38%)
DFML 11.56 Decreased By ▼ -0.24 (-2.03%)
DGKC 42.03 Decreased By ▼ -1.17 (-2.71%)
EPCL 45.66 Decreased By ▼ -0.33 (-0.72%)
FCCL 11.60 Decreased By ▼ -0.25 (-2.11%)
FFL 5.78 Decreased By ▼ -0.10 (-1.7%)
FLYNG 5.94 Decreased By ▼ -0.13 (-2.14%)
GGL 10.88 Decreased By ▼ -0.37 (-3.29%)
HUBC 67.40 Decreased By ▼ -0.48 (-0.71%)
HUMNL 5.59 Decreased By ▼ -0.05 (-0.89%)
KAPCO 24.38 Decreased By ▼ -0.47 (-1.89%)
KEL 2.11 Decreased By ▼ -0.02 (-0.94%)
LOTCHEM 24.92 Decreased By ▼ -0.08 (-0.32%)
MLCF 24.58 Decreased By ▼ -0.29 (-1.17%)
NETSOL 74.12 Decreased By ▼ -2.08 (-2.73%)
OGDC 84.67 Decreased By ▼ -1.19 (-1.39%)
PAEL 10.61 Decreased By ▼ -0.44 (-3.98%)
PIBTL 3.91 Decreased By ▼ -0.07 (-1.76%)
PPL 64.81 Decreased By ▼ -1.19 (-1.8%)
PRL 12.74 Decreased By ▼ -0.21 (-1.62%)
SILK 0.87 Decreased By ▼ -0.01 (-1.14%)
SNGP 39.41 Decreased By ▼ -1.34 (-3.29%)
TELE 7.06 Decreased By ▼ -0.42 (-5.61%)
TPLP 14.70 Decreased By ▼ -0.39 (-2.58%)
TRG 107.60 Decreased By ▼ -2.85 (-2.58%)
UNITY 13.37 Decreased By ▼ -0.14 (-1.04%)
WTL 1.20 Decreased By ▼ -0.01 (-0.83%)
BR100 4,040 Decreased By -40.6 (-0.99%)
BR30 14,413 Decreased By -217.8 (-1.49%)
KSE100 39,942 Decreased By -434.1 (-1.08%)
KSE30 14,739 Decreased By -177.2 (-1.19%)
World

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

  • Study was conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others
Published December 17, 2021
Follow us

COVID-19 vaccines from US drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.

The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.

Vaccines from Moderna, AstraZeneca and Pfizer and partner BioNTech retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.

WHO warns Covid variant Omicron risk ‘very high’

The study, conducted by Humabs Biomed SA, a unit of Vir Biotechnology and the University of Washington, among others, also found the decrease was less pronounced for vaccinated individuals who were previously infected.

The study also found that while the effectiveness of GlaxoSmithKline and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.

The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.

WHO sees unprecedented Omicron spread, 'probably' in most countries

In a real-world study published this week, it was seen that Pfizer-BioNTech's COVID-19 vaccine has been less effective in South Africa at keeping people infected with the virus out of hospital since the Omicron variant emerged last month.

Comments

Comments are closed.

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron: study

Free flour: Punjab govt to provide 20kg bags from 29th

Support price of wheat in Balochistan now equal to those in other provinces

ECC told: G-B working on targeted wheat subsidy plan

Free flour: PML-N seeks to regain a foothold in Punjab

PSA seeks annual limit of $800m for solar imports

Militancy crisis: WB to mull over $50m project for Fata, KP families’ succor

'Not a crime': Trump dismisses NY probe at Texas rally

Marriyum heaps criticism on IK

'Great misery': Kuwait political crisis drags down economy

Punjab-KP polls,general election: IK accuses govt of deep-rooted ambivalence